Inactive Instrument

Motif Bio plc

Equities

MTFB

GB00BVVT4H71

Biotechnology & Medical Research

Motif Bio plc Reports Earnings Results for the Full Year Ended December 31, 2020

May 10, 2021 at 11:48 am EDT

Motif Bio plc announced earnings results for the full year ended December 31, 2020. For the full year, the company announced operating loss was USD 891,000. Net loss was USD 734,000.

Latest news about Motif Bio plc

MOTF BIO : BiVictriX Debuts on London's AIM Segment After $10 Million IPO	21-08-11	MT
Motif Bio plc Announces Board Appointments	21-06-14	CI
BiVictriX Therapeutics Ltd. cancelled the acquisition of Motif Bio plc in a reverse merger transaction.	21-06-13	CI
Motif Bio plc Reports Earnings Results for the Full Year Ended December 31, 2020	21-05-10	CI
Motif Bio plc Announces Board Changes	21-05-10	CI
Orange Avenue Technologies LLC entered into a Stock Purchase Agreement to acquire Motif BioSciences, Inc. from Motif Bio plc	21-02-25	CI
Motif Bio : Signs Reverse Takeover of Antibody-Drug Conjugate Company	21-01-27	MT
BiVictriX Therapeutics Ltd. entered into a sale and purchase agreement to acquire Motif Bio plc for £5.5 million in a reverse merger transaction.	21-01-26	CI
Motif Bio plc Reports Earnings Results for the Half Year Ended June 30, 2020	20-10-12	CI
Motif Bio plc Reports Earnings Results for the Full Year Ended December 31, 2019	20-09-01	CI
Motif Bio plc Announces Delay in Publication of Final Results for the Year Ended 31 December 2019	20-06-22	CI
Motif Bio Appoints Adviser for Reverse Takeover Candidate	20-06-01	CI
Motif Seeks Reverse Takeover Candidate	20-05-05	CI
Motif Bio plc Announces Management Changes	20-05-04	CI
Motif Bio plc and Motif BioSciences Inc. Enter into Loan Amendment and Release Agreement with Hercules Capital In	20-01-29	CI
Motif Bio plc(NasdaqCM:MTFB) dropped from NASDAQ Composite Index	19-12-16	CI
Motif Bio plc Announces Directorate Changes	19-11-18	CI
Motif Bio plc Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-30	CI
Motif Bio plc and Hercules Capital Amend Loan and Security Agreement	19-09-02	CI
Motif Bio plc to Evaluate Iclaprim Activity Against Listeria	19-08-19	CI
Motif Bio plc Amends Loan and Security Agreement with Hercules Capital, Inc	19-08-01	CI
Motif Bio Confirms Meeting Date with U.S. FDA Regarding Iclaprim	19-07-26	CI
Motif Bio plc Submits Meeting Request and Package to the U.S. Food & Drug Administration Related for iclaprim	19-07-15	CI
Motif Bio plc Presents New Iclaprim Data at ASM Microbe 2019	19-06-24	CI
Transcript : Motif Bio plc - Special Call	19-06-06

Chart Motif Bio plc

Duration

Period

More charts

Company Profile

Motif Bio plc is a United Kingdom-based shell company. The Company is not engaged in any operation.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs